JP2018507854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507854A5 JP2018507854A5 JP2017542389A JP2017542389A JP2018507854A5 JP 2018507854 A5 JP2018507854 A5 JP 2018507854A5 JP 2017542389 A JP2017542389 A JP 2017542389A JP 2017542389 A JP2017542389 A JP 2017542389A JP 2018507854 A5 JP2018507854 A5 JP 2018507854A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mutant
- motif
- amino acid
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000539 amino acid group Chemical group 0.000 claims description 25
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims description 19
- 108010079505 Endostatins Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 108091006112 ATPases Proteins 0.000 claims description 10
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 10
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 238000010353 genetic engineering Methods 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- -1 aromatic amino acid Chemical class 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 101500026378 Homo sapiens Endostatin Proteins 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510079486 | 2015-02-13 | ||
| CN201510079486.7 | 2015-02-13 | ||
| CN201510736184 | 2015-11-02 | ||
| CN201510736184.2 | 2015-11-02 | ||
| PCT/CN2016/073773 WO2016127948A1 (zh) | 2015-02-13 | 2016-02-14 | 一种重组蛋白质药物的分子设计 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507854A JP2018507854A (ja) | 2018-03-22 |
| JP2018507854A5 true JP2018507854A5 (enExample) | 2019-03-14 |
| JP6896636B2 JP6896636B2 (ja) | 2021-06-30 |
Family
ID=56614147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542389A Active JP6896636B2 (ja) | 2015-02-13 | 2016-02-14 | 組換えタンパク質薬の分子設計 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10869910B2 (enExample) |
| EP (1) | EP3269731B1 (enExample) |
| JP (1) | JP6896636B2 (enExample) |
| CN (2) | CN114249816B (enExample) |
| AU (2) | AU2016218635B2 (enExample) |
| CA (1) | CA3014538A1 (enExample) |
| DK (1) | DK3269731T5 (enExample) |
| WO (1) | WO2016127948A1 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890155B (zh) * | 2010-05-25 | 2012-07-25 | 江苏先声药物研究有限公司 | 一种药物组合物及其应用 |
| WO2013034116A1 (zh) * | 2011-09-09 | 2013-03-14 | 清华大学 | 对atp结合位点进行突变的血管内皮抑制素突变体 |
| CN107148277B (zh) * | 2014-11-03 | 2022-03-22 | 清华大学 | 一种抑制脂肪细胞分化和胰岛素耐受的药物 |
-
2016
- 2016-02-14 CN CN202111201002.3A patent/CN114249816B/zh active Active
- 2016-02-14 EP EP16748749.5A patent/EP3269731B1/en active Active
- 2016-02-14 US US15/550,751 patent/US10869910B2/en active Active
- 2016-02-14 CN CN201680010044.XA patent/CN107428809B/zh active Active
- 2016-02-14 DK DK16748749.5T patent/DK3269731T5/da active
- 2016-02-14 CA CA3014538A patent/CA3014538A1/en active Pending
- 2016-02-14 AU AU2016218635A patent/AU2016218635B2/en active Active
- 2016-02-14 JP JP2017542389A patent/JP6896636B2/ja active Active
- 2016-02-14 WO PCT/CN2016/073773 patent/WO2016127948A1/zh not_active Ceased
-
2020
- 2020-09-28 US US17/035,497 patent/US20210085754A1/en active Pending
- 2020-10-13 AU AU2020256316A patent/AU2020256316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7166933B2 (ja) | プログラム細胞死を誘導するｃｄ４７のアゴニスト剤及びプログラム細胞死の欠陥と関連する疾患の治療におけるそれらの使用 | |
| CA2387184C (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway | |
| JP5734865B2 (ja) | 選択性に優れた抗がんキメラペプチド | |
| JP2008501310A (ja) | 胃腸障害の治療のための方法および組成物 | |
| JP2016540739A (ja) | 神経保護ペプチド | |
| US11041157B2 (en) | Slit2D2-HSA fusion protein and use thereof against tumours | |
| WO2012127475A1 (en) | Neuroprotective peptides | |
| JP4902919B2 (ja) | ペプチド作成の方法 | |
| JP4934034B2 (ja) | 神経分化誘導ペプチド及びその利用 | |
| JP6953579B2 (ja) | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 | |
| CA2916584A1 (en) | Pro-apoptotic ras and raf peptides | |
| JP2013535965A5 (enExample) | ||
| JP6903633B2 (ja) | 腫瘍抑制ペプチド | |
| CN117157308A (zh) | 细胞穿膜肽变体及其用途 | |
| US20160272690A1 (en) | Yap protein inhibiting polypeptide and application thereof | |
| JP2018507854A5 (enExample) | ||
| KR100641535B1 (ko) | 브이이지에프 펩티드 및 그 용도 | |
| JPH04182497A (ja) | ポリペプチド | |
| JP2024518125A (ja) | 組織再生の促進に有用なｈｍｇｂ１関連ポリペプチド、それを含む組成物及びその使用 | |
| JP7791593B2 (ja) | 細胞透過性ペプチド変異体およびその用途 | |
| KR20220137876A (ko) | 조직 재생의 촉진에 유용한 hmgb1과 관련된 폴리펩티드, 이를 포함하는 조성물, 및 이들의 용도 | |
| WO2015135925A1 (en) | Respiratory syncytial virus (rsv) replication inhibitors | |
| CN100480264C (zh) | 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列 | |
| CN102378765A (zh) | 拮抗糖胺聚糖的mcp-1突变体及其用途 | |
| WO2019049144A1 (en) | COMPOSITIONS FOR THE INHIBITION OF METHYLTRANSFERASE SETD6 |